Information on EC 3.5.1.88 - peptide deformylase

New: Word Map on EC 3.5.1.88
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Specify your search results
Mark a special word or phrase in this record:
Search Reference ID:
Select one or more organisms in this record:
Show additional data
Do not include text mining results
Include (text mining) results (more...)
Include results (AMENDA + additional results, but less precise; more...)

The enzyme appears in viruses and cellular organisms

EC NUMBER
COMMENTARY hide
3.5.1.88
-
RECOMMENDED NAME
GeneOntology No.
peptide deformylase
REACTION
REACTION DIAGRAM
COMMENTARY hide
ORGANISM
UNIPROT
LITERATURE
formyl-L-methionyl peptide + H2O = formate + methionyl peptide
show the reaction diagram
-
-
-
-
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
deformylation
formylation
-
-
hydrolysis of amide bond
SYSTEMATIC NAME
IUBMB Comments
formyl-L-methionyl peptide amidohydrolase
Requires Fe(II). Also requires at least a dipeptide for an efficient rate of reaction. N-terminal L-methionine is a prerequisite for activity but the enzyme has broad specificity at other positions. Differs in substrate specifity from EC 3.5.1.31 (formylmethionine deformylase).
CAS REGISTRY NUMBER
COMMENTARY hide
369636-51-1
-
37289-08-0
-
9032-86-4
-
9054-98-2
-
ORGANISM
COMMENTARY hide
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
-
-
-
Manually annotated by BRENDA team
Borrelia burgdorferi
-
-
-
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
gene def
-
-
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
3D homology model of the matured soybean PDF2 based on the X-ray structure of the homologous enzyme from Plasmodium falciparum
-
-
Manually annotated by BRENDA team
strain SS1
Uniprot
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
strain Philadelphia 1
-
-
Manually annotated by BRENDA team
Legionella pneumophila Philadelphia 1
strain Philadelphia 1
-
-
Manually annotated by BRENDA team
no activity in Caenorhabditis elegans
-
-
-
Manually annotated by BRENDA team
no activity in Saccharomyces cerevisiae
-
-
-
Manually annotated by BRENDA team
-
UniProt
Manually annotated by BRENDA team
strain ATCC27853
Uniprot
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
strain ATCC2913
Uniprot
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
strain RN4220
Uniprot
Manually annotated by BRENDA team
Staphylococcus enteridis
-
-
-
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
Staphylococcus non-hemolyticus
-
-
-
Manually annotated by BRENDA team
strain ATCC6305
Uniprot
Manually annotated by BRENDA team
Streptomyces pneumoniae
-
-
-
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
GENERAL INFORMATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
evolution
malfunction
-
inhibition of the MEK/ERK, but not PI3K or mTOR, pathway reduces the expression of the enzyme in both colon and lung cancer cell lines
metabolism
-
peptide deformylase (PDF) is a protein of the N-terminal methionine excision pathway that removes formylmethionine from mitochondrial-encoded proteins. PDF is crucial in maintaining mitochondrial function
physiological function
additional information
-
enzyme structure comparison to plant enzyme from Arabidopsis thaliana, overview. A cysteine residue is involved in metal coordination within the active site, together with the two histidines from the thermolysin-metzincin HEXXH motif. The natural product tripeptide Met-Ala-Ser does not change the unfolding process of the protein, binding structure of the peptide to the enzyme, overview
SUBSTRATE
PRODUCT                       
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
(RS)-phenylalanine nitrile + formate
(S)-N-formyl-phenylalanine nitrile
show the reaction diagram
-
-
99% (S)-enantiomer
-
r
2-formyloxycaproylleucyl-p-nitroanilide + H2O
?
show the reaction diagram
-
esterase activity, 10fold lower activity compared to N-formyl-Met-Leu-p-nitroanilide
-
-
?
formyl-L-Met-Leu-p-nitroanilide + H2O
formate + Met-Leu-p-nitroanilide
show the reaction diagram
formyl-L-methionyl peptide + H2O
formate + L-methionyl peptide
show the reaction diagram
formyl-L-methionyl peptide + H2O
formate + methionyl peptide
show the reaction diagram
formyl-MAHA + H2O
formate + MAHA
show the reaction diagram
-
peptide substrate derived from mitochondrial cytochrome c oxidase subunit II
-
-
?
formyl-MEHQ + H2O
formate + MEHQ
show the reaction diagram
-
-
-
-
?
formyl-Met-Ala + H2O
formate + Met-Ala
show the reaction diagram
formyl-Met-Ala-His-Ala + H2O
formate + methionyl-Ala-His-Ala
show the reaction diagram
fMAHA
-
-
?
formyl-Met-Ala-His-Ala-Ala-Gln + H2O
formate + Met-Ala-His-Ala-Ala-Gln
show the reaction diagram
formyl-Met-Ala-Lys-Tyr + H2O
formate + Met-Ala-Lys-Tyr
show the reaction diagram
formyl-Met-Ala-Ser + H2O
formate + Met-Ala-Ser
show the reaction diagram
formyl-Met-Ala-Ser + H2O
formate + methionyl-Ala-His-Ala
show the reaction diagram
fMAS
-
-
?
formyl-Met-Gly-Gly-CH3 + H2O
formate + Met-Gly-Gly-CH3
show the reaction diagram
-
substrate used in QM-MM model
-
-
?
formyl-Met-Leu-p-nitroanilide + H2O
formate + Met-Leu-p-nitroanilide
show the reaction diagram
formyl-Met-Thr-Gln-Ser-His + H2O
formate + Met-Thr-Gln-Ser-His
show the reaction diagram
formyl-Met-Thr-Met-His + H2O
formate + methionyl-Thr-Met-His
show the reaction diagram
fMTMH
-
-
?
formyl-Met-Thr-Met-His-Thr-Thr + H2O
formate + Met-Thr-Met-His-Thr-Thr
show the reaction diagram
formyl-Met-Thr-Pro-Met-Arg-Lys + H2O
?
show the reaction diagram
-
-
-
-
?
formyl-MFAD + H2O
formate + MFAD
show the reaction diagram
-
peptide substrate derived from mitochondrial cytochrome c oxidase subunit I
-
-
?
formyl-MFHQ + H2O
formate + MMFQ
show the reaction diagram
-
-
-
-
?
formyl-MGHQ + H2O
formate + MGHQ
show the reaction diagram
-
-
-
-
?
formyl-MLHQ + H2O
formate + MLHQ
show the reaction diagram
-
-
-
-
?
formyl-MLKL + H2O
formate + MLKL
show the reaction diagram
-
peptide substrate derived from mitochondrial NADH dehydrogenase subunit 4
-
-
?
formyl-MMYA + H2O
formate + MMYA
show the reaction diagram
-
peptide substrate derived from mitochondrial NADH dehydrogenase subunit 6
-
-
?
formyl-MNFA + H2O
formate + MNFA
show the reaction diagram
-
peptide substrate derived from mitochondrial NADH dehydrogenase subunit 3
-
-
?
formyl-MNPL + H2O
formate + MNPL
show the reaction diagram
-
peptide substrate derived from mitochondrial NADH dehydrogenase subunit 2
-
-
?
formyl-MPQL + H2O
formate + MPQL
show the reaction diagram
-
peptide substrate derived from mitochondrial ATP synthase F0 subunit 8
-
-
?
formyl-MRHQ + H2O
formate + MRHQ
show the reaction diagram
-
-
-
-
?
formyl-MTHQ + H2O
formate + MTHQ
show the reaction diagram
formyl-MTMH + H2O
formate + MTMH
show the reaction diagram
-
peptide substrate derived from mitochondrial NADH dehydrogenase subunit 5
-
-
?
formyl-MTPM + H2O
formate + MTPM
show the reaction diagram
-
peptide substrate derived from mitochondrial cytochrome b
-
-
?
formyl-MVHQ + H2O
formate + MVHQ
show the reaction diagram
-
-
-
-
?
N-(alpha-difluoroacetyl)-Met-Leu-p-nitroanilide + H2O
difluoroacetic acid + Met-Leu-p-nitroanilide
show the reaction diagram
-
-
-
?
N-(alpha-fluoroacetyl)-Met-Leu-p-nitroanilide + H2O
fluoroacetic acid + Met-Leu-p-nitroanilide
show the reaction diagram
-
-
-
?
N-formyl-1-(1-naphthyl)ethylamine + H2O
(1R)-1-naphthalen-1-ylethanamine + formate
show the reaction diagram
-
-
90% (R)-enantiomer
-
?
N-formyl-3-amino-3-phenylpropionic acid + H2O
(R)-3-amino-3-phenylpropionic acid + formate
show the reaction diagram
-
-
100% (R)-enantiomer
-
?
N-formyl-Ala-Gly-Ser-Glu + H2O
formate + Ala-Gly-Ser-Glu
show the reaction diagram
N-formyl-alaninol + H2O
(S)-alaninol + formate
show the reaction diagram
-
-
85.6% (S)-enantiomer
-
?
N-formyl-alpha-methyl-phenylglycine amide + H2O
(S)-alpha-methyl-phenylglycine amide + formate
show the reaction diagram
-
-
100% (S)-enantiomer
-
?
N-formyl-beta-thiaphenyl-Lys-p-nitroanilide + H2O
formate + thiophenol + NH3 + Lys-p-nitroanilide
show the reaction diagram
N-formyl-beta-thiaphenylalanyl-peptide + H2O
formate + thiophenol + NH3 + alanyl-peptide
show the reaction diagram
N-formyl-His-Ala-Ser-Arg + H2O
formate + His-Ala-Ser-Arg
show the reaction diagram
-
greatly attenuated activity, preference for N-terminal methionine
-
?
N-formyl-L-Met-D-Ala-Ser-Arg + H2O
formate + L-Met-D-Ala-Ser-Arg
show the reaction diagram
-
strong requirement for L-methionine, but D-amino acids tolerated in other positions
-
?
N-formyl-L-Met-L-Ala-L-Ser + H2O
formate + L-Met-L-Ala-L-Ser
show the reaction diagram
N-formyl-L-Met-L-Leu-4-nitroanilide + H2O
formate + L-Met-L-Leu-4-nitroanilide
show the reaction diagram
-
-
-
-
?
N-formyl-L-Met-Val + H2O
formate + L-Met-Val
show the reaction diagram
N-formyl-L-methionine + H2O
formate + L-methionine
show the reaction diagram
N-formyl-L-methionine polypeptide + H2O
formate + methionine-polypeptide
show the reaction diagram
N-formyl-L-methionine-polypeptide + H2O
formate + L-methionine-polypeptide
show the reaction diagram
N-formyl-L-Nle-L-Ala-L-Ser + H2O
formate + L-Nle-L-Ala-L-Ser
show the reaction diagram
-
norleucine is the only excepted substitution for methionine
-
?
N-formyl-Leu-Tle-NHCH3 + H2O
(S)-Leu-(S)-Tle-NHCH3
show the reaction diagram
-
Tle i.e. tert-leucine
Tle i.e. tert-leucine, 94% (S,S)-diastereomer
-
?
N-formyl-m-methoxyphenylalanine nitrile + H2O
(S)-m-methoxyphenylalanine nitrile + formate
show the reaction diagram
-
-
99% (S)-enantiomer
-
?
N-formyl-Met + H2O
formate + Met
show the reaction diagram
N-formyl-Met-Ala + H2O
formate + Met-Ala
show the reaction diagram
N-formyl-Met-Ala + H2O
Met-Ala + formate
show the reaction diagram
-
-
-
-
?
N-formyl-Met-Ala(OCH3) + H2O
formate + Met-Ala(OCH3)
show the reaction diagram
N-formyl-Met-Ala-Phe-Tyr-beta-Ala-Arg + H2O
formate + Met-Ala-Phe-Tyr-beta-Ala-Arg
show the reaction diagram
-
-
-
?
N-formyl-Met-Ala-Ser + H2O
formate + Met-Ala-Ser
show the reaction diagram
N-formyl-Met-Leu-Glu + H2O
formate + Met-Leu-Glu
show the reaction diagram
N-formyl-Met-Leu-NH2 + H2O
formate + Met-Leu-NH2
show the reaction diagram
-
-
-
?
N-formyl-Met-Leu-p-nitroanilide + H2O
formate + Met-Leu-p-nitroanilide
show the reaction diagram
N-formyl-Met-Leu-Phe + H2O
formate + Met-Leu-Phe
show the reaction diagram
N-formyl-Met-Ser-Asn-Glu + H2O
formate + Met-Ser-Asn-Glu
show the reaction diagram
N-formyl-Met-Val-Ser + H2O
formate + Met-Val-Ser
show the reaction diagram
N-formyl-Met-Xaa-Xbb-Tyr + H2O
formate + Met-Xaa-Xbb-Tyr
show the reaction diagram
-
consesus sequence for best substrates, Xaa: any amino acid except for Asp and Glu, Xbb: Lys, Arg, Tyr or Phe
-
?
N-formyl-Nle-Ala(NH2) + H2O
formate + Nle-Ala(NH2)
show the reaction diagram
N-formyl-Nle-Ala-Ser + H2O
formate + Nle-Ala-Ser
show the reaction diagram
N-formyl-Nle-Arg(NH2) + H2O
formate + Nle-Arg(NH2)
show the reaction diagram
N-formyl-Nle-Asn(NH2) + H2O
formate + Nle-Asn(NH2)
show the reaction diagram
-
-
-
-
?
N-formyl-Nle-Asp(NH2) + H2O
formate + Nle-Asp(NH2)
show the reaction diagram
N-formyl-Nle-Gln(NH2) + H2O
formate + Nle-Gln(NH2)
show the reaction diagram
-
-
-
-
?
N-formyl-Nle-Glu(NH2) + H2O
formate + Nle-Glu(NH2)
show the reaction diagram
-
-
-
-
?
N-formyl-Nle-Gly(NH2) + H2O
formate + Nle-Gly(NH2)
show the reaction diagram
N-formyl-Nle-His(NH2) + H2O
formate + Nle-His(NH2)
show the reaction diagram
-
-
-
-
?
N-formyl-Nle-Leu(NH2) + H2O
formate + Nle-Leu(NH2)
show the reaction diagram
N-formyl-Nle-Lys(NH2) + H2O
formate + Nle-Lys(NH2)
show the reaction diagram
-
-
-
-
?
N-formyl-Nle-Met(NH2) + H2O
formate + Nle-Met(NH2)
show the reaction diagram
-
-
-
-
?
N-formyl-Nle-NH(CH3) + H2O
formate + Nle-NH(CH3)
show the reaction diagram
N-formyl-Nle-NH2 + H2O
formate + Nle-Nle-NH2
show the reaction diagram
N-formyl-Nle-Nle(NH2) + H2O
formate + Nle-Nle(NH2)
show the reaction diagram
-
-
-
-
?
N-formyl-Nle-Phe(NH2) + H2O
formate + Nle-Phe(NH2)
show the reaction diagram
-
-
-
-
?
N-formyl-Nle-Pro(NH2) + H2O
formate + Nle-Pro(NH2)
show the reaction diagram
-
-
-
-
?
N-formyl-Nle-Ser(NH2) + H2O
formate + Nle-Ser(NH2)
show the reaction diagram
N-formyl-Nle-Thr(NH2) + H2O
formate + Nle-Thr(NH2)
show the reaction diagram
-
-
-
-
?
N-formyl-Nle-Trp(NH2) + H2O
formate + Nle-Trp(NH2)
show the reaction diagram
-
-
-
-
?
N-formyl-Nle-Tyr(NH2) + H2O
formate + Nle-Tyr(NH2)
show the reaction diagram
-
-
-
-
?
N-formyl-Nle-Val(NH2) + H2O
formate + Nle-Val(NH2)
show the reaction diagram
-
-
-
-
?
N-formyl-Nva-Ala-Ser + H2O
formate + Nva-Ala-Ser
show the reaction diagram
N-formyl-Phe-Ala-Ser + H2O
formate + Phe-Ala-Ser
show the reaction diagram
N-formyl-Phe-Tyr-Phe + H2O
formate + Phe-Tyr-Phe
show the reaction diagram
-
only N-terminal Phe can replace Met
-
?
N-formyl-Phe-Tyr-Phe-His-beta-Ala-Arg + H2O
formate + Phe-Tyr-Phe-His-beta-Ala-Arg
show the reaction diagram
-
-
-
?
N-formyl-Phe-Tyr-Tyr + H2O
formate + Phe-Tyr-Tyr
show the reaction diagram
-
only N-terminal Phe can replace Met
-
?
N-formyl-phenylalanine nitrile + H2O
(S)-phenylalanine nitrile + formate
show the reaction diagram
-
-
98.8% (S)-enantiomer
-
?
N-formyl-phenylglycine + H2O
(S)-phenylglycine + formate
show the reaction diagram
-
-
99.6% (S)-enantiomer
-
?
N-formyl-phenylglycine amide + H2O
(S)-phenylglycine amide + formate
show the reaction diagram
-
-
99.7% (S)-enantiomer
-
?
N-formyl-phenylglycinol + H2O
(S)-phenylglycinol + formate
show the reaction diagram
-
-
90.5-93.3% (S)-enantiomer, depending on method
-
?
N-formyl-tert-leucine amide + H2O
(S)-tert-leucine amide + formate
show the reaction diagram
-
-
100% (S)-enantiomer
-
?
N-formyl-thiaphenyl-Ala-Leu-p-nitroanilide + H2O
formate + thiophenol + NH3 + Ala-Leu-p-nitroanilide
show the reaction diagram
-
excellent substrate
-
?
N-formyl-valine nitrile + H2O
(S)-valine nitrile + formate
show the reaction diagram
-
-
98.8% (S)-enantiomer
-
?
N-formylmethionine-alanine + H2O
formate + methionyl-alanine
show the reaction diagram
-
-
-
-
?
additional information
?
-
NATURAL SUBSTRATES
NATURAL PRODUCTS
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
formyl-L-methionyl peptide + H2O
formate + L-methionyl peptide
show the reaction diagram
formyl-L-methionyl peptide + H2O
formate + methionyl peptide
show the reaction diagram
N-formyl-L-methionine polypeptide + H2O
formate + methionine-polypeptide
show the reaction diagram
N-formyl-L-methionine-polypeptide + H2O
formate + L-methionine-polypeptide
show the reaction diagram
additional information
?
-
METALS and IONS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
Fe3+
-
more stable activity than with Fe2+
Iron
-
iron-containing enzyme
Mn2+
-
250fold increase of activity
Zinc
-
ratio of results of zinc to protein is 1:1
additional information
INHIBITORS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
(1-hydroxyaminomethyl-2-phenylethyl)carbamic acid tert-butyl ester
; AtPDF2
(1-hydroxycarbamoylmethyl-2-phenylethyl)carbamic acid tert-butyl ester
AtPDF2
(2E)-3-(2,5-dihydroxyphenyl)-1-(2-hydroxy-4,6-dimethoxyphenyl)prop-2-en-1-one
-
(2R)-N-[(1S)-1-(dimethylcarbamoyl)-2,2-dimethylpropyl]-2-[[formyl(hydroxy)amino]methyl]hexanamide
(2R)-N-[(1S)-5-amino-1-(hexylcarbamoyl)pentyl]-2-[[formyl(hydroxy)amino]methyl]heptanamide
-
-
(2R)-N-[(2S)-1-{4-[(2H-1,3-benzodioxol-5-yl)methyl]piperazin-1-yl}-3,3-dimethyl-1-oxobutan-2-yl]-2-(cyclopentylmethyl)-3-[formyl(hydroxy)amino]propanamide
(2R)-N-[(3S)-2-[4-(1,3-benzodioxol-5-ylmethyl)piperazin-1-yl]-4,4-dimethylpent-1-en-3-yl]-2-[[formyl(hydroxy)amino]methyl]hexanamide
(2R)-N4-hydroxy-N1-[(2R)-1-[(2R)-2-(hydroxymethyl)pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]-2-pentylbutanediamide
-
(2S)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(4-methoxyphenyl)-2,5-dihydro-1H-pyrrole-2-carboxamide
(2S)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(4-nitrophenyl)-2,5-dihydro-1H-pyrrole-2-carboxamide
(2S)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(5-methyl-1,3-thiazol-2-yl)-2,5-dihydro-1H-pyrrole-2-carboxamide
(2S)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(pyridin-2-yl)-2,5-dihydro-1H-pyrrole-2-carboxamide
(2S)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-phenyl-2,5-dihydro-1H-pyrrole-2-carboxamide
(2S)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-[(1R)-1-phenylethyl]-2,5-dihydro-1H-pyrrole-2-carboxamide
(2S)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-[(1S)-1-phenylethyl]-2,5-dihydro-1H-pyrrole-2-carboxamide
(2S)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-[5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl]-2,5-dihydro-1H-pyrrole-2-carboxamide
(2S)-2-[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]pent-4-ynoic acid
-
(2S)-N-(2-bromophenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-2,5-dihydro-1H-pyrrole-2-carboxamide
(2S)-N-(2-chlorophenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-2,5-dihydro-1H-pyrrole-2-carboxamide
(2S)-N-(3-bromophenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-2,5-dihydro-1H-pyrrole-2-carboxamide
(2S)-N-(4-bromophenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-2,5-dihydro-1H-pyrrole-2-carboxamide
(2S)-N-(4-chlorophenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-2,5-dihydro-1H-pyrrole-2-carboxamide
(2S)-N-(4-fluorophenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-2,5-dihydro-1H-pyrrole-2-carboxamide
(2S)-N-(5-fluoro-1-oxidopyridin-2-yl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-2,5-dihydro-1H-pyrrole-2-carboxamide
(2S)-N-(5-fluoropyridin-2-yl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-2,5-dihydro-1H-pyrrole-2-carboxamide
(2S)-N-cyclopropyl-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-2,5-dihydro-1H-pyrrole-2-carboxamide
(2S,3aR,7aS)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-N-(5-methylpyridin-2-yl)octahydro-1H-indole-2-carboxamide
(2S,3aR,7aS)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-N-(5-methylthiazol-2-yl)octahydro-1H-indole-2-carboxamide
(2S,3aR,7aS)-1-((R)-3-cyclopentyl-2-((N-hydroxyformamido)methyl)propanoyl)-N-(5-fluoropyridin-2-yl)octahydro-1H-indole-2-carboxamide
(2S,3aR,7aS)-1-((R)-3-cyclopentyl-2-((N-hydroxyformamido)methyl)propanoyl)-N-(5-methylpyridin-2-yl)octahydro-1H-indole-2-carboxamide
(2S,3aR,7aS)-1-((R)-3-cyclopentyl-2-((N-hydroxyformamido)methyl)propanoyl)-N-(5-methylthiazol-2-yl)octahydro-1H-indole-2-carboxamide
(2S,3R,4S,5R,6R)-2-[(5-bromo-1H-indol-3-yl)oxy]-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
-
(2S,3R,4S,5S,6R)-2-[(5-bromo-6-chloro-1H-indol-3-yl)oxy]-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
-
(2S,4S)-1-((R)-3-cyclopentyl-2-((N-hydroxyformamido)methyl)propanoyl)-4-fluoro-N-(5-methylthiazol-2-yl)pyrrolidine-2-carboxamide
(2S,4S)-1-((R)-3-cyclopentyl-2-((N-hydroxyformamido)methyl)propanoyl)-4-methyl-N-(5-methylthiazol-2-yl)pyrrolidine-2-carboxamide
(2S,4S)-4-fluoro-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-N-(5-methylthiazol-2-yl)pyrrolidine-2-carboxamide
(3R)-3-[[(2S)-2-(1,3-benzoxazol-2-yl)pyrrolidin-1-yl]carbonyl]-N-hydroxyheptanamide
-
(3R)-3-[[(2S)-2-(1,3-benzoxazol-2-yl)pyrrolidin-1-yl]carbonyl]heptanoic acid
-
(3R)-3-[[(2S)-2-(1H-benzimidazol-2-yl)pyrrolidin-1-yl]carbonyl]-N-hydroxyheptanamide
-
(3R)-3-[[(2S)-2-(1H-benzimidazol-2-yl)pyrrolidin-1-yl]carbonyl]heptanoic acid
-
(E)-N-phenethyl-3-(3,4-diacetoxyphenyl)acrylamide
IC50: 0.00125 mM
(R)-2-[(formyl-hydroxy-amino)-methyl]-hexanoic acid ((S)-5-amino-1-phenylcarbamoyl-pentyl)-amide
-
-
(R)-2-[(formyl-hydroxy-amino)-methyl]-hexanoic acid [(S)-5-amino-1-((R)-2-isopropoxymethyl-pyrrolidine-1-carbonyl)-pentyl]-amide
-
-
(R)-2-[(formyl-hydroxy-amino)-methyl]-hexanoic acid [(S)-5-amino-1-((S)-2-isopropoxymethyl-pyrrolidine-1-carbonyl)-pentyl]-amide
-
-
(RS)- and (SR)-3-[(RS)-benzenesulfinyl]heptanoic acid hydroxyamide
-
mixture of both components, IC50: 0.0001 mM, possible antimicrobial agent
(RS)-3-(phenylsulfonyl)heptanoic acid hydroxyamide
-
IC50: 0.035 micro molar, possible antimicrobial agent
(S)-1-((R)-2-(((formyl-hydroxyamino)methyl)hexanoyl)-N-(5-fluoro-1-oxido-pyridin)-2-yl)-2,5-dihydro-1H-pyrrole-2-carboxamide
(S)-1-((R)-2-((formyl(hydroxy)amino)methyl)hexanoyl)-N-(2-bromophenyl)-2,5-dihydro-1H-pyrrole-2-carboxamide
(S)-1-((R)-2-((formyl(hydroxy)amino)methyl)hexanoyl)-N-(2-chlorophenyl)-2,5-dihydro-1H-pyrrole-2-carboxamide
(S)-1-((R)-2-((formyl(hydroxy)amino)methyl)hexanoyl)-N-(3-bromophenyl)-2,5-dihydro-1H-pyrrole-2-carboxamide
(S)-1-((R)-2-((formyl(hydroxy)amino)methyl)hexanoyl)-N-(4-bromophenyl)-2,5-dihydro-1H-pyrrole-2-carboxamide
(S)-1-((R)-2-((formyl(hydroxy)amino)methyl)hexanoyl)-N-(4-chlorophenyl)-2,5-dihydro-1H-pyrrole-2-carboxamide
(S)-1-((R)-2-((formyl-hydroxyamino)methyl)hexanoyl)-N-(5-fluoropyridin-2-yl)-2,5-dihydro-1H-pyrrole-2-carboxamide
(S)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-4-methylene-N-(5-methylthiazol-2-yl)pyrrolidine-2-carboxamide
(S)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-4-methylene-N-phenylpyrrolidine-2-carboxamide
(S)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-N-((R)-1-phenylethyl)-2,5-dihydro-1H-pyrrole-2-carboxamide
(S)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-N-((S)-1-phenylethyl)-2,5-dihydro-1H-pyrrole-2-carboxamide
(S)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-N-(4-methoxyphenyl)-2,5-dihydro-1H-pyrrole-2-carboxamide
(S)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-N-(4-nitrophenyl)-2,5-dihydro-1H-pyrrole-2-carboxamide
(S)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-N-(5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl)-2,5-dihydro-1H-pyrrole-2-carboxamide
(S)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-N-(5-methylthiazol-2-yl)-2,5-dihydro-1H-pyrrole-2-carboxamide
(S)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-N-(pyridin-2-yl)-2,5-dihydro-1H-pyrrole-2-carboxamide
(S)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-Nphenyl-2,5-dihydro-1H-pyrrole-2-carboxamide
(S)-1-((R)-3-cyclopentyl-2-((N-hydroxyformamido)methyl)propanoyl)-N-((S)-1-phenylethyl)-2,5-dihydro-1H-pyrrole-2-carboxamide
(S)-1-((R)-3-cyclopentyl-2-((N-hydroxyformamido)methyl)propanoyl)-N-(4-fluorophenyl)-2,5-dihydro-1H-pyrrole-2-carboxamide
(S)-1-((R)-3-cyclopentyl-2-((N-hydroxyformamido)methyl)propanoyl)-N-(5-fluoropyridin-2-yl)-2,5-dihydro-1H-pyrrole-2-carboxamide
(S)-1-((R)-3-cyclopentyl-2-((N-hydroxyformamido)methyl)propanoyl)-N-phenyl-2,5-dihydro-1H-pyrrole-2-carboxamide
(S)-1-((R)-3-cyclopentyl-2-((N-hydroxyformamido)pyrrole-2-carboxamide methyl)propanoyl)-N-(5-methylthiazol-2-yl)-2,5-dihydro-1HS
(S)-1-((R)-3-cyclopentyl-2-((N-hydroxyformamido)pyrrole-2-carboxamide-methyl)propanoyl)-N-(5-methylthiazol-2-yl)-2,5-dihydro-1HS
-
-
(S)-2-O-(H-phosphonoxy)-L-caproyl-L-Leu-p-nitroanilide
-
similar inhibition of Fe2+- and Co2+-bound enzyme
-
(S)-2-O-(phosphonoxy)-L-caproyl-L-leucyl-p-nitroanilide
-
-
(S)-N-(4-fluorophenyl)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-2,5-dihydro-1H-pyrrole-2-carboxamide
(S)-N-(4-fluorophenyl)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-4-methylenepyrrolidine-2-carboxamide
(S)-N-(5-fluoropyridin-2-yl)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-4-methylenepyrrolidine-2-carboxamide
(S)-N-cyclopropyl-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-2,5-dihydro-1H-pyrrole-2-carboxamide
1,10-phenanthroline
1,2-Ethanedithiol
-
irreversible
1,3-propanedithiol
-
irreversible
1,5-pentanedithiol
-
-
1-(2-[[formyl(hydroxy)amino]methyl]hexanoyl)-4-methylidene-N,N-dimorpholin-4-yl-L-prolinamide
1-(3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl)-4-methylidene-N,N-dimorpholin-4-yl-L-prolinamide
1-(5-bromo-1H-indol-3-yl)-3-hydroxypropan-2-one
AtPDF2
1-(5-bromo-2-methyl-1H-indol-3-yl)-N-hydroxymethanamine
1-(methylamino)-3-[2-(prop-2-en-1-yl)phenoxy]propan-2-ol
-
1-[(2-methoxyphenyl)carbamoyl]prolyl-N2-(cyclopentylmethyl)-N-hydroxyglycinamide
-
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(2-methylphenyl)-L-prolinamide
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(3-methylphenyl)-L-prolinamide
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(4-methoxyphenyl)-L-prolinamide
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(4-methylphenyl)-L-prolinamide
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(4-morpholin-4-ylphenyl)-L-prolinamide
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(4-piperidin-1-ylphenyl)-L-prolinamide
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(4-pyrrolidin-1-ylphenyl)-L-prolinamide
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-[4-(1H-pyrrol-1-yl)phenyl]-L-prolinamide
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-[4-(4-methylpiperazin-1-yl)phenyl]-L-prolinamide
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-[4-(4-oxidomorpholin-4-yl)phenyl]-L-prolinamide
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(2,2-dimethylpropanoyl)-L-prolinamide
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(2-methylpropanoyl)-L-prolinamide
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(3-methylbutanoyl)-L-prolinamide
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(cyclopropylcarbonyl)-L-prolinamide
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(ethoxycarbonyl)-L-prolinamide
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(ethylcarbamoyl)-L-prolinamide
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(methoxyacetyl)-L-prolinamide
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(methoxycarbonyl)-L-prolinamide
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(methylcarbamoyl)-L-prolinamide
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(prop-2-en-1-ylcarbamoyl)-L-prolinamide
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[(2-hydroxyethyl)carbamoyl]-L-prolinamide
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[(3-hydroxypropyl)carbamoyl]-L-prolinamide
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[(3-phenylpropyl)carbamoyl]-L-prolinamide
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[(cyclopentyloxy)carbonyl]-L-prolinamide
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[(propan-2-yloxy)carbonyl]-L-prolinamide
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[(tetrahydro-2H-pyran-4-yloxy)carbonyl]-L-prolinamide
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[[2-(1H-imidazol-4-yl)ethyl]carbamoyl]-L-prolinamide
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[[2-(pyrazin-2-yl)ethyl]carbamoyl]-L-prolinamide
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[[2-(pyridin-2-yl)ethyl]carbamoyl]-L-prolinamide
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[[2-(pyridin-3-yl)ethyl]carbamoyl]-L-prolinamide
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[[2-(pyridin-4-yl)ethyl]carbamoyl]-L-prolinamide
1-[5-bromo-2-methyl-1-(phenylsulfonyl)-1H-indol-3-yl]-N-hydroxymethanamine
2',2'-bisepigallocatechin monogallate
-
-
2,3-dimercapto-1-propanesulfonic acid
-
-
2,3-dimercapto-1-propanol
-
-
2-((2S,4S)-1-((R)-3-cyclopentyl-2-((N-hydroxyformamido)methyl)propanoyl)-4-fluoropyrrolidine-2-carboxamido)-5-fluoropyridine 1-oxide
2-((2S,4S)-1-((R)-3-cyclopentyl-2-((N-hydroxyformamido)methyl)propanoyl)-4-methylpyrrolidine-2-carboxamido)-5-fluoropyridine 1-oxide
2-((S)-1-((R)-3-cyclopentyl-2-((N-hydroxyformamido)methyl)propanoyl)-2,5-dihydro-1H-pyrrole-2-carboxamido)-5-fluoropyridine 1-oxide
2-(1-benzyl-5-chloro-2,2-dioxido-1,4-dihydro-3H-2,1,3-benzothiadiazin-3-yl)-N-hydroxyacetamide
-
IC50: 0.002 mM
2-(1-butyl-5-chloro-2,2-dioxido-1,4-dihydro-3H-2,1,3-benzothiadiazin-3-yl)-N-hydroxyacetamide
-
IC50: 0.00059 mM
2-(2,2-dioxido-1,4-dihydro-3H-2,1,3-benzothiadiazin-3-yl)-N-hydroxyacetamide
-
IC50: 0.00076 mM
2-(4-benzyl-3-oxo-3,4-dihydro-2H-1,4-benzothiazin-2-yl)-N-oxoacetamide
-
2-(4-fluoro-1H-indol-3-yl)-N-hydroxyacetamide
2-(4-[2-[(2,5-difluorophenyl)amino]-2-oxoethyl]-3-oxo-3,4-dihydro-2H-1,4-benzothiazin-2-yl)-N-oxoacetamide
-
2-(5-bromo-1-cyclopropyl-2,2-dioxido-1,4-dihydro-3H-2,1,3-benzothiadiazin-3-yl)-N-hydroxyacetamide
-
IC50: 0.000069 mM
2-(5-bromo-1H-indol-3-yl)-N-hydroxyacetamide
2-(5-bromo-2,2-dioxido-1,4-dihydro-3H-2,1,3-benzothiadiazin-3-yl)-N-hydroxyacetamide
-
IC50: 0.000098 mM
2-(5-bromo-2-methyl-1H-indol-3-yl)-N-hydroxyacetamide
2-(5-bromo-2-methyl-1H-indolyl)-N-hydroxyacetamide
2-(5-bromo-2-oxo-1,4-dihydroquinazolin-3(2H)-yl)-N-hydroxyacetamide
-
IC50: 0.000049 mM
2-(5-chloro-1-cyclopropyl-2,2-dioxido-1,4-dihydro-3H-2,1,3-benzothiadiazin-3-yl)-N-hydroxyacetamide
-
IC50: 0.00011 mM
2-(5-chloro-1H-indol-3-yl)-N-hydroxyacetamide
2-(5-chloro-2,2-dioxido-1,4-dihydro-3H-2,1,3-benzothiadiazin-3-yl)-N-hydroxyacetamide
-
inhibitor shows good selectivity for peptide deformylase over several endoproteases including matrix metalloproteases, however it shows only weak antibacterial activity. IC50: 0.00012 mM
2-(5-chloro-2-oxo-1,4-dihydroquinazolin-3(2H)-yl)-N-hydroxyacetamide
-
inhibitor shows good selectivity for peptide deformylase over several endoproteases including matrix metalloproteases, however it shows only weak antibacterial activity. IC50: 0.00031 mM
2-(5-chloro-2-oxo-1,4-dihydroquinazolin-3(2H)-yl)acetohydrazide
-
IC50: 0.027 mM
2-(5-fluoro-1H-indol-3-yl)-N-hydroxyacetamide
2-(5-fluoro-2,2-dioxido-1,4-dihydro-3H-2,1,3-benzothiadiazin-3-yl)-N-hydroxyacetamide
-
IC50: 0.00087 mM
2-(5-fluoro-2-oxo-1,4-dihydroquinazolin-3(2H)-yl)-N-hydroxyacetamide
-
IC50: 0.00087 mM
2-(5-methoxy-1H-indol-3-yl)-N-hydroxyacetamide
; AtPDF2
2-(6-bromo-1H-indol-3-yl)-N-hydroxyacetamide
2-(biphenyl-4-yl)-N-oxoacetamide
-
2-(indol-3-yl)-N-hydroxyacetamide
2-amino-5-mercapto-1,3,4-thiadiazole
-
slow-binding inhibitor of PDF when dissolved only in dimethylformamide, but not in any other solvent, and aged (via the formation of a disulfide bond) to a dimeric form
2-amino-N-[(1S,2S)-1-hydroxy-1-phenylpropan-2-yl]-N-methylacetamide
-
2-butyl-5,7-dimethyl-3-[2''-(1H-tetrazol-5-ylmethyl)-[1,1',4',1'']terphenyl-4-yl]-3H-imidazo[4,5-b]pyridine
-
belongs to a class of angiotensin II receptor antagonists, potent inhibitor, IC50: 0.0076 mM
2-mercaptoethanol
-
30% inhibition at 1 mM
2-oxo-pyrrolidine with chelators
-
-
-
2-phenylethanamine
2-thioxo-4-thiazolidinone N-hexanoic acid
-
IC50 against Escherichia coli peptide deformylase: 0.00166 mM
2-thioxo-4-thiazolidinones
-
-
-
2-[(12R,17aS)-1,13-dioxohexadecahydro-1H-pyrrolo[1,2-a][1,4]diazacyclopentadecin-12-yl]-N-hydroxyacetamide
-
-
2-[(3-aminopropanoyl)amino]-3-phenylpropanoic acid
-
2-[(3S,6R)-3-tert-butyl-2,5-dioxo-1,4-diazacyclopentadecan-6-yl]-N-hydroxyacetamide
-
-
2-[2,2-dioxido-5-(trifluoromethyl)-1,4-dihydro-3H-2,1,3-benzothiadiazin-3-yl]-N-hydroxyacetamide
-
IC50: 0.00013 mM
2-[2-[(2-hydroxyethyl)amino]-1H-benzimidazol-1-yl]-1-phenylethanone
-
2-[4-(3,3-dimethyl-2-oxobutyl)-3-oxo-3,4-dihydro-2H-1,4-benzothiazin-2-yl]-N-oxoacetamide
-
2-[4-(3-methylbutyl)-3-oxo-3,4-dihydro-2H-1,4-benzothiazin-2-yl]-N-oxoacetamide
-
2-[4-(cyclobutylmethyl)-3-oxo-3,4-dihydro-2H-1,4-benzothiazin-2-yl]-N-oxoacetamide
-
2-[5-chloro-2,2-dioxido-1-(3-phenylpropyl)-1,4-dihydro-3H-2,1,3-benzothiadiazin-3-yl]-N-hydroxyacetamide
-
IC50: 0.00029 mM
3-(3-acetylsulfanyl-2-oxopropyl)indole-1-carboxylic acid benzyl ester
AtPDF2
3-carboxymethylindol-1-carboxylic acid benzyl ester
; AtPDF2
3-methoxycatechol
-
-
3-methyl-N-(1,3-thiazol-2-ylcarbamoyl)-L-valyl-N2-(cyclopentylmethyl)-N-hydroxyglycinamide
-
3-methyl-N-(2-methylpropanoyl)-L-valyl-N2-(cyclopentylmethyl)-N-hydroxyglycinamide
-
3-methyl-N-(morpholin-4-ylcarbonyl)-L-valyl-N2-(cyclopentylmethyl)-N-hydroxyglycinamide
-
3-methyl-N-(phenylcarbamoyl)-L-valyl-N2-(cyclopentylmethyl)-N-hydroxyglycinamide
-
3-methyl-N-(piperidin-1-ylcarbonyl)-L-valyl-N2-(cyclopentylmethyl)-N-hydroxyglycinamide
-
3-methyl-N-(pyridin-2-ylcarbamoyl)-L-valyl-N2-(cyclopentylmethyl)-N-hydroxyglycinamide
-
3-methyl-N-(pyridin-3-ylcarbamoyl)-L-valyl-N2-(cyclopentylmethyl)-N-hydroxyglycinamide
-
3-methyl-N-(pyridin-4-ylcarbamoyl)-L-valyl-N2-(cyclopentylmethyl)-N-hydroxyglycinamide
-
3-methyl-N-(thiophen-2-ylcarbonyl)-L-valyl-N2-(cyclopentylmethyl)-N-hydroxyglycinamide
-
3-methyl-N-[methyl(phenyl)carbamoyl]-L-valyl-N2-(cyclopentylmethyl)-N-hydroxyglycinamide
-
3-[5'-benzyl-2'-(1H-tetrazol-5-yl)-biphenyl-4-yl]-2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridine
-
potent inhibitor, IC50: 0.0342 mM, the acidic moiety forms direct ionic interactions with active site metal cation
5'-phosphothiorate modified antisense oligodeoxyribonucleotides
-
-
-
5-(1,1-dimethyl-propyl)-4'-(2-ethyl-5,7-dimethyl-imidazo[4,5-b]pyridin-3-yl)-biphenyl-2-sulfonylcarbamate
-
competitive inhibition, IC50: 0.015 mM, the acidic moiety forms direct ionic interactions with active site metal cation
-
5-bromo-3-hydroxycarbamoylmethylindole-1-carboxylic acid benzyl ester
5-chloro-2-propyl-3-[2''-(1H-tetrazol-5-ylmethyl)-[1,1',4',1'']terphenyl-4-yl]-3H-imidazo[4,5-b]pyridine
-
belongs to a broad class of angiotensin II receptor antagonists, potent competitive inhibitor, IC50: 0.0039 mM, the acidic moiety forms direct ionic interactions with active site metal cation
5-fluoro-2-((2S,4S)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-4-methylpyrrolidine-2-carboxamido)pyridine 1-oxide
5-fluoro-2-((2S,4S)-4-fluoro-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)pyrrolidine-2-carboxamido)pyridine1-oxide
5-fluoro-2-((S)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-4-methylenepyrrolidine-2-carboxamido)pyridine 1-oxide
5-[[(2-chlorophenyl)sulfanyl]methyl]-N-hydroxy-1,2-oxazole-3-carboxamide
-
5-[[(3,4-dichlorophenyl)sulfanyl]methyl]-N-hydroxy-1,2-oxazole-3-carboxamide
-
5-[[(3-chlorophenyl)sulfonyl]methyl]-N-hydroxy-1,2-oxazole-3-carboxamide
-
5-[[(4-chlorophenyl)sulfanyl]methyl]-N-hydroxy-1,2-oxazole-3-carboxamide
-
5-[[(4-methoxyphenyl)sulfonyl]methyl]-1,2-oxazole-3-carbohydrazide
-
7,8-dihydroxyflavone
-
-
8-hydroxyquinoline
-
50% inhibition at 2 mM
actinonin
aldehyde peptide
-
IC50 against Escherichia coli peptide deformylase: 0.01 mM
-
alkyl-succinate-proline hydroxamate
-
IC50 against Escherichia coli peptide deformylase: 0.000004-0.000010 mM
analogues of actinonin
-
35 different compounds were synthesized and compared to the inhibitory activity of actinonin
-
BB-3497
BB-81384
BB-83698
BB83698
benzimidazole N-formyl hydroxylamine
-
-
benzothiazinone derivatives
-
IC50: 0.000005 mM
-
benzothiazolylidene hydroxamic acid derivatives
-
IC50 against Escherichia coli peptide deformylase: 0.00104 mM
-
benzyl 5-bromo-3-[2-(hydroxyamino)-2-oxoethyl]-1H-indole-1-carboxylate
beta-sulfonylhydroxamic acid
-
IC50 against Escherichia coli peptide deformylase: 0.000016 mM
caffeic acid phenethyl ester
-
CAPE, an active component of propolis, 75% inhibition at 0.01 mM, the competitive inhibitor blocks the substrate entrance, preventing substrate from approaching the active site, but CAPE does not have chelate interaction with HpPDF and does not disrupt the metal-dependent catalysis
carbamate N-formyl hydroxylamine
-
-
chloranil
-
-
Ciprofloxacin
Co(III)1
-
peptide cleaving catalyst
Diethylenetriaminepentaacetic acid
diprop-2-en-1-yl (2S)-2-aminobutanedioate
-
epigallocatechin 3,5-digallate
-
-
epitheaflavin monogallate
-
-
ethyl 2-amino-3-(benzylsulfanyl)propanoate
-
ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate
-
Fe3+
-
inactivation due to oxidation of Fe2+ to Fe3+
flavimycin A
-
a dimeric 1,3-dihydroisobenzofuran, isolated from cultures of Aspergillus flavipes, structure analysis by NMR and mass spectrometry, the inhibitor exists as epimeric mixture at C-1 through fast hemiacetal-aldehyde tautomerism. The compound has antibacterial activity against Staphylococcus aureus including MRSA, with MIC values of 0.032-0.064 mg/mL
-
flavimycin B
-
a dimeric 1,3-dihydroisobenzofuran, isolated from cultures of Aspergillus flavipes, structure analysis by NMR and mass spectrometry, the inhibitor exists as epimeric mixture at C-1 through fast hemiacetal-aldehyde tautomerism. The compound has antibacterial activity against Staphylococcus aureus including MRSA, with MIC values of 0.032-0.064 mg/mL
formylmethionine
-
-
glutathione
-
10% inhibition at 1 mM
GSK1322322
hematein
-
-
hematoxylin
-
-
heteroarylaryl(P2'/P3')N-formyl hydroxylamine
-
-
hydantoin
-
IC50 against Escherichia coli peptide deformylase: 0.0002 mM
hydrazide N-formyl hydroxylamine
-
-
imino[(5-methoxy-5-oxo-4-[2-(sulfanylmethyl)hexanoyl]aminopentyl)amino]methaneamine
irigenol
-
-
isoxazole-3-hydroxamic acid derivatives
-
IC50 against Escherichia coli peptide deformylase: 0.0034 mM
-
isoxazole-3-hydroxamic acids
LBM-415
LBM415
linezolid
methyl 4-(2-benzylbenzoyl)-2,5-dimethyl-1H-pyrrole-3-carboxylate
-
methyl-1-(sulfanylmethyl)hexanoate
N-((5-bromo-2-methyl-1(phenylsulfonyl)-1H-indol-3-yl)methyl) hydroxylamine
AtPDF2
N-((R)-2-(cyclopentylmethyl)-3-((S)-2-(morpholine-4-carbonyl)-2,5-dihydro-1H-pyrrol-1-yl)-3-oxopropyl)-N-hydroxyformamide
N-(1-benzenesulfonyl-5-bromo-2-methyl-1H-indol-3-ylmethyl)-N-hydroxyformamide
N-(2-methoxybenzoyl)-3-methyl-L-valyl-N2-(cyclopentylmethyl)-N-hydroxyglycinamide
-
N-(2-[[(2S)-2-[[1,3-bis(4-fluorophenyl)triazan-2-yl]carbonyl]-4-methylidenepyrrolidin-1-yl]carbonyl]hexyl)-N-hydroxyformamide
N-(2-[[(2S)-2-[[1,3-bis(4-hydroxyphenyl)triazan-2-yl]carbonyl]-4-methylidenepyrrolidin-1-yl]carbonyl]hexyl)-N-hydroxyformamide
N-(2-[[(2S)-2-[[1,3-bis(5-fluoro-1-oxidopyridin-2-yl)triazan-2-yl]carbonyl]-4-methylidenepyrrolidin-1-yl]carbonyl]hexyl)-N-hydroxyformamide
N-(2-[[(2S)-2-[[1,3-bis(5-fluoropyridin-2-yl)triazan-2-yl]carbonyl]-4-methylidenepyrrolidin-1-yl]carbonyl]hexyl)-N-hydroxyformamide
N-(2-[[(2S)-2-[[1,3-bis(5-methyl-1,3-thiazol-2-yl)triazan-2-yl]carbonyl]-4-methylidenepyrrolidin-1-yl]carbonyl]hexyl)-N-hydroxyformamide
N-(3,4-difluorophenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
N-(3-chloro-4-morpholin-4-ylphenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
N-(3-chloro-4-piperidin-1-ylphenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
N-(3-chloro-4-pyrrolidin-1-ylphenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
N-(3-fluoro-4-morpholin-4-ylphenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
N-(3-fluoro-4-piperidin-1-ylphenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
N-(3-fluoro-4-pyrrolidin-1-ylphenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
N-(3-tert-butyl-2,5-dioxo-1,4-diaza-cycloheptadec-6-yl)-methyl-N-hydroxy-formamide
-
-
N-(3-tert-butyl-2,5-dioxo-1,4-diaza-cyclohexadec-6-yl)-methyl-N-hydroxy-formamide
-
-
N-(3-tert-butyl-2,5-dioxo-1,4-diaza-cycloicos-6-yl)-methyl-N-hydroxy-formamide
-
-
N-(3-tert-butyl-2,5-dioxo-1,4-diaza-cyclopentadec-6-yl)-methyl-N-hydroxy-formamide
-
-
N-(3-tert-butyl-2,5-dioxo-1,4-diaza-cyclotridec-6-yl)-methyl-N-hydroxy-formamide
-
-
N-(4-chlorophenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
N-(4-fluorophenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
N-(5-fluoro-1-hydroxypyridin-1-ium-2-yl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]prolinamide
N-(5-fluoro-1-hydroxypyridin-1-ium-2-yl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]prolinamideampicillin
-
-
-
N-(5-fluoro-1-hydroxypyridin-1-ium-2-yl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]prolinamideN-hydroxy-N-((R)-2-((S)-2-(morpholine-4-carbonyl)-2,5-dihydro-1H-pyrrole-1-carbonyl)hexyl)formamide
-
-
-
N-(5-fluoro-1-oxidopyridin-2-yl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
-
-
N-(benzylcarbamoyl)-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
N-(benzyloxy)-2-(3-oxo-3,4-dihydro-2H-1,4-benzothiazin-2-yl)acetamide
-
N-(cyclobutylcarbamoyl)-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
N-(cyclobutylcarbonyl)-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
N-(cyclohexylcarbamoyl)-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
N-(cyclohexylcarbamoyl)-3-methyl-L-valyl-N2-(cyclopentylmethyl)-N-hydroxyglycinamide
-
N-(cyclohexylcarbonyl)-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
N-(cyclopentylcarbamoyl)-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
N-(cyclopentylcarbonyl)-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
N-(R)-[2-(hydroxyaminocarbonyl)methyl]-4-methylpentanoyl-L-naphthylalanyl-L-alanine amide
-
-
N-(tert-butoxycarbonyl)-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
N-(tert-butylcarbamoyl)-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
N-acetyl-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
N-alkyl urea hydroxamate
-
IC50 against Escherichia coli peptide deformylase: 0.000003 mM
N-benzoyl-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
N-benzoyl-3-methyl-L-valyl-N2-(cyclopentylmethyl)-N-hydroxyglycinamide
-
N-benzyloxycarbonyl-Leu-norleucinal
N-carbamoyl-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
N-formyl-L-methionylalanine
-
inhibition above 4 mM
N-formyl-Met-Ala-Ser
-
the enzyme activity of truncated PDF-1DeltaN37 is inhibited by an excess of N-formyl-Met-Ala-Ser substrate
N-formyl-N-hydroxy-2-(3-benzoylphenoxy)ethylamine
N-formyl-N-hydroxy-3-phenylpropylamine
N-formylhydroxylamine
-
i.e. LBM-415
-
N-hydroxy urea
-
IC50 against Escherichia coli peptide deformylase: 0.0022 mM
N-hydroxy-2-(1H-indol-3-yl)acetamide
N-hydroxy-2-(2-oxo-1,4-dihydroquinazolin-3(2H)-yl)acetamide
-
IC50: 0.0029 mM
N-hydroxy-2-(5-methoxy-1H-indol-3-yl)acetamide
N-hydroxy-2-(substituted phenyl) acetamide
-
-
N-hydroxy-2-[2-oxo-5-(trifluoromethyl)-1,4-dihydroquinazolin-3(2H)-yl]acetamide
-
IC50: 0.00023 mM
N-hydroxy-5-([[2-(propan-2-yl)phenyl]sulfanyl]methyl)-1,2-oxazole-3-carboxamide
-
N-hydroxy-5-([[4-(trifluoromethyl)phenyl]sulfanyl]methyl)-1,2-oxazole-3-carboxamide
-
N-hydroxy-N-((R)-2-((S)-2-(morpholine-4-carbonyl)-2,5-dihydro-1H-pyrrole-1-carbonyl)hexyl)formamide
N-hydroxy-N-((R)-2-((S)-4-methylene-2-(morpholine-4-carbonyl)pyrrolidine-1-carbonyl)hexyl)formamide
N-hydroxy-N-(3-hydrazino-3-oxopropyl)formamide
-
-
N-hydroxy-N-[(2R)-2-[[(2S)-2-(morpholin-4-ylcarbonyl)-2,5-dihydro-1H-pyrrol-1-yl]carbonyl]hexyl]formamide
N-hydroxy-N-[3-(6-methylpyridine-2-yl)propyl]formamide
N-methoxy-2-(3-oxo-3,4-dihydro-2H-1,4-benzothiazin-2-yl)acetamide
-
N-methoxy-N-methyl-2-(3-oxo-3,4-dihydro-2H-1,4-benzothiazin-2-yl)acetamide
-
N-oxo-2-[3-oxo-4-(2-phenylethyl)-3,4-dihydro-2H-1,4-benzothiazin-2-yl]acetamide
-
N-oxo-2-[3-oxo-4-(tetrahydro-2H-pyran-2-ylmethyl)-3,4-dihydro-2H-1,4-benzothiazin-2-yl]acetamide
-
N-oxo-2-[3-oxo-4-[2-oxo-2-(pyrrolidin-1-yl)ethyl]-3,4-dihydro-2H-1,4-benzothiazin-2-yl]acetamide
-
N-substituted methionine hydrazide
-
IC50 against Escherichia coli peptide deformylase: 0.2 mM
N-sulfonyl-L-Val-L-Leu-hydroxamate
-
-
N-trans-caffeoyltyramine
IC50: 0.0108 mM
N-[(2-aminoethyl)carbamoyl]-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
N-[(2-methoxyethyl)carbamoyl]-3-methyl-L-valyl-N2-(cyclopentylmethyl)-N-hydroxyglycinamide
-
N-[(2-methoxyphenyl)carbamoyl]-3-methyl-L-valyl-N-hydroxy-N2-(3-methylbutyl)glycinamide
-
N-[(2-methoxyphenyl)carbamoyl]-3-methyl-L-valyl-N2-(2-cyclopentylethyl)-N-hydroxyglycinamide
-
N-[(2-methoxyphenyl)carbamoyl]-3-methyl-L-valyl-N2-(cyclobutylmethyl)-N-hydroxyglycinamide
-
N-[(2-methoxyphenyl)carbamoyl]-3-methyl-L-valyl-N2-(cyclopentylmethyl)-N-hydroxyglycinamide
N-[(2-methoxyphenyl)carbamoyl]-3-methyl-L-valyl-N2-(cyclopropylmethyl)-N-hydroxyglycinamide
-
N-[(2-methoxyphenyl)carbamoyl]alanyl-N2-(cyclopentylmethyl)-N-hydroxyglycinamide
-
N-[(2-methoxyphenyl)carbamoyl]leucyl-N2-(cyclopentylmethyl)-N-hydroxyglycinamide
-
N-[(2-methoxyphenyl)carbamoyl]norleucyl-N2-(cyclopentylmethyl)-N-hydroxyglycinamide
-
N-[(2-methoxyphenyl)carbamoyl]phenylalanyl-N2-(cyclopentylmethyl)-N-hydroxyglycinamide
-
N-[(2-methoxyphenyl)carbamoyl]valyl-N2-(cyclopentylmethyl)-N-hydroxyglycinamide
-
N-[(2R)-2-(cyclopentylmethyl)-3-(2-[5-fluoro-6-[(9aS)-hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-2-methylpyrimidin-4-yl]hydrazinyl)-3-oxopropyl]-N-hydroxyformamide
-
-
N-[(2R)-2-(cyclopentylmethyl)-3-(2-{5-fluoro-6-[(9aS)-hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-2-methylpyrimidin-4-yl}hydrazinyl)-3-oxopropyl]-N-hydroxyformamide
N-[(2R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl]-L-tryptophan methylamide
-
-
N-[(2R)-2-[[(2S)-2-(1,3-benzoxazol-2-yl)pyrrolidin-1-yl]carbonyl]heptyl]-N-hydroxyformamide
-
N-[(2R)-2-[[(2S)-2-(1,3-benzoxazol-2-yl)pyrrolidin-1-yl]carbonyl]hexyl]-N-hydroxyformamide
-
N-[(2R)-2-[[(2S)-2-(1,3-benzoxazol-2-yl)pyrrolidin-1-yl]carbonyl]pentyl]-N-hydroxyformamide
-
N-[(2R)-2-[[(2S)-2-(1H-benzimidazol-2-yl)pyrrolidin-1-yl]carbonyl]heptyl]-N-hydroxyformamide
-
N-[(2R)-2-[[(2S)-2-(1H-benzimidazol-2-yl)pyrrolidin-1-yl]carbonyl]hexyl]-N-hydroxyformamide
-
N-[(2R)-2-[[(2S)-2-(1H-benzimidazol-2-yl)pyrrolidin-1-yl]carbonyl]pentyl]-N-hydroxyformamide
-
N-[(2R)-3-[(2S)-2-(1,3-benzoxazol-2-yl)pyrrolidin-1-yl]-2-(cyclopentylmethyl)-3-oxopropyl]-N-hydroxyformamide
-
N-[(2R)-3-[(2S)-2-(1,3-benzoxazol-2-yl)pyrrolidin-1-yl]-2-benzyl-3-oxopropyl]-N-hydroxyformamide
-
N-[(2R)-3-[(2S)-2-(1H-benzimidazol-2-yl)pyrrolidin-1-yl]-2-(cyclopentylmethyl)-3-oxopropyl]-N-hydroxyformamide
-
N-[(2R)-3-[(2S)-2-(1H-benzimidazol-2-yl)pyrrolidin-1-yl]-2-benzyl-3-oxopropyl]-N-hydroxyformamide
-
N-[(2R,4S)-2-butyl-4-[[(2-fluorophenyl)carbamoyl]amino]-5-methyl-3-oxohexyl]-N-hydroxyformamide
-
binding structure, overview
N-[(2R,4S)-2-butyl-5-methyl-4-[[(5-methylpyridin-2-yl)carbamoyl]amino]-3-oxohexyl]-N-hydroxyformamide
-
binding structure, overview
N-[(3,5-difluorophenyl)carbamoyl]-3-methyl-L-valyl-N2-(cyclopentylmethyl)-N-hydroxyglycinamide
-
binding structure, overview
N-[(3-amino-3-oxopropyl)carbamoyl]-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
N-[(cyclobutyloxy)carbonyl]-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
N-[(cyclohexyloxy)carbonyl]-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
N-[2-(5-bromo-2-methyl-1H-indole-3-yl)methyl]hydroxylamine
; AtPDF2
N-[2-(cyclopentylmethyl)-3-[(2S)-2-[(1,3-dicyclopropyltriazan-2-yl)carbonyl]-4-methylidenepyrrolidin-1-yl]-3-oxopropyl]-N-hydroxyformamide
N-[2-([(2S)-2-[(1,3-diphenyltriazan-2-yl)carbonyl]-4-methylidenepyrrolidin-1-yl]carbonyl)hexyl]-N-hydroxyformamide
N-[3-(4-acetamidobutyl)-2,5-dioxo-1,4-diaza-cyclopentadec-6-yl]methyl-N-hydroxy-formamide
-
-
N-[3-(4-aminobutyl)-2,5-dioxo-1,4-diazacycloicos-6-yl]methyl-N-hydroxyformamide
-
-
N-[3-(4-aminobutyl)-2,5-dioxo-1,4-diazacyclopentadec-6-yl]methyl-N-hydroxyformamide
-
-
N-[3-chloro-4-(4-oxidomorpholin-4-yl)phenyl]-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
N-[3-fluoro-4-(1-oxidopiperidin-1-yl)phenyl]-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
N-[3-fluoro-4-(1H-pyrrol-1-yl)phenyl]-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
N-[3-fluoro-4-(4-methyl-1,4-diazepan-1-yl)phenyl]-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
N-[3-fluoro-4-(4-oxidomorpholin-4-yl)phenyl]-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
N-[3-[(2S)-2-[[1,3-bis(4-fluorophenyl)triazan-2-yl]carbonyl]-4-methylidenepyrrolidin-1-yl]-2-(cyclopentylmethyl)-3-oxopropyl]-N-hydroxyformamide
N-[3-[(2S)-2-[[1,3-bis(5-fluoro-1-oxidopyridin-2-yl)triazan-2-yl]carbonyl]-4-methylidenepyrrolidin-1-yl]-2-(cyclopentylmethyl)-3-oxopropyl]-N-hydroxyformamide
N-[3-[(2S)-2-[[1,3-bis(5-fluoropyridin-2-yl)triazan-2-yl]carbonyl]-4-methylidenepyrrolidin-1-yl]-2-(cyclopentylmethyl)-3-oxopropyl]-N-hydroxyformamide
N-[3-[(2S)-2-[[1,3-bis(5-methyl-1,3-thiazol-2-yl)triazan-2-yl]carbonyl]-4-methylidenepyrrolidin-1-yl]-2-(cyclopentylmethyl)-3-oxopropyl]-N-hydroxyformamide
N-[4-(4-ethylpiperazin-1-yl)-3-fluorophenyl]-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
N-[4-(4-ethylpiperazin-1-yl)phenyl]-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
N-[4-(trifluoromethyl)benzoyl]-L-Met
-
time-dependent inhibition of zinc and cobalt deformylase, inhibition of full-length Co-PDF is competitive
N-[4-(trifluoromethyl)benzoyl]-L-Met hydrazide
-
time-dependent inhibition of zinc and cobalt deformylase
N-[[(3S,6R)-3-tert-butyl-2,5-dioxo-1,4-diazacyclopentadecan-6-yl]methyl]-N-hydroxyformamide
Borrelia burgdorferi
-
Zn-BbPDF1-HT
N-[[5-bromo-2-methyl-1-(phenylsulfonyl)-1H-indol-3-yl]methyl]-N-hydroxyformamide
N2-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-phenyl-L-lysinamide
-
-
naphthalen-1-yl[[3-(trifluoromethyl)benzyl]amino]acetic acid
-
p-chloromercuribenzoate
-
potent inhibitor, IC50: 0.07 mM
penicillin
Peptide aldehydes
Phe-Arg-beta-naphthylamide
-
-
piperidin-4-yl [1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolyl]carbamate
Polyethylene glycol
-
-
polylethylene glycol
-
competitive inhibitor with respect to formylmethionine
-
propan-2-amine
pseudopeptide metabolites
-
IC50 against Escherichia coli peptide deformylase: 0.000030 mM
-
Purpurogallin
-
-
pyrogallin
-
-
pyrrolidine bicyclic(P2'/P3')compounds
-
-
-
quinalizarin
-
-
quinazoline hydroxamic acid
-
IC50 against Escherichia coli peptide deformylase: 0.00012 mM
reverse hydroxamate
-
British Biotech BB-83698
reverse hydroxamates
-
-
-
siRNA HsPDF 581-601
-
transfection of HeLa cells
-
siRNA HsPDF 659-679
-
transfection of HeLa cells
-
SKI-AC-1
-
IC50: 0.000072 mM, actionin analog
SKI-AC-10
-
IC50: 0.000078 mM, actionin analog
SKI-AC-11101
-
IC50: 0.000076 mM, actionin analog
-
SKI-AC-111101
-
IC50: 0.0000600 mM, actionin analog
SKI-AC-111110
-
IC50: 0.000427 mM, actionin analog
-
SKI-AC-111111
-
IC50: 0.000069 mM, actionin analog
SKI-AC-111112
-
IC50: 0.000234 mM, actionin analog
-
SKI-AC-111113
-
IC50: 0.000177 mM, actionin analog
-
SKI-AC-111114
-
IC50: 0.000300 mM, actionin analog
-
SKI-AC-11112
-
IC50: 0.000365 mM, actionin analog
-
SKI-AC-11113
-
IC50: 0.000500 mM, actionin analog
-
SKI-AC-11114
-
IC50: 0.000276 mM, actionin analog
-
SKI-AC-11115
-
IC50: 0.000473 mM, actionin analog
-
SKI-AC-11116
-
IC50: 0.000335 mM, actionin analog
-
SKI-AC-11117
-
IC50: 0.000086 mM, actionin analog
SKI-AC-11118
-
IC50: 0.000115 mM, actionin analog
SKI-AC-11119
-
IC50: 0.000134 mM, actionin analog
-
SKI-AC-11128
-
IC50: 0.000522 mM, actionin analog
-
SKI-AC-11138
-
IC50: 0.000500 mM, actionin analog
-
SKI-AC-11148
-
IC50: 0.0000600 mM, actionin analog
-
SKI-AC-11158
-
IC50: 0.000500 mM, actionin analog
-
SKI-AC-11168
-
IC50: 0.000192 mM, actionin analog
-
SKI-AC-11178
-
IC50: 0.000200 mM, actionin analog
-
SKI-AC-11188
-
IC50: 0.000120 mM, actionin analog
-
SKI-AC-11198
-
IC50: 0.000090 mM, actionin analog
SKI-AC-3
-
IC50: 0.000500 mM, actionin analog
-
SKI-AC-5
-
IC50: 0.000400 mM, actionin analog
-
SKI-AC-51121
-
IC50: 0.000400 mM, actionin analog
-
SKI-AC-6
-
IC50: 0.000097 mM, actionin analog
SKI-AC-8
-
IC50: 0.000093 mM, actionin analog
SKI-AC-9
-
IC50: 0.000151 mM, actionin analog
-
SKI-AC-I-18
-
IC50: 0.000404 mM, actionin analog
-
SKI-AC-I-19
-
IC50: 0.000239 mM, actionin analog
-
tert-butyl 1-[(2R)-2-[2-(hydroxyamino)-2-oxoethyl]hexanoyl]-L-prolinate
theaflavin
-
-
theaflavin monogallate
-
-
thio peptide
-
IC50 against Escherichia coli peptide deformylase: 0.000019 mM, thiol chelating group combined with the best substrate motif
-
thioacetic acid S-[3-(5-bromo-1H-indol-3-yl)-2-oxopropyl] ester
AtPDF2
thioacetic acid S-[3-(indol-3-yl)-2-oxopropyl] ester
; AtPDF2
thiol peptide
-
IC50 against Escherichia coli peptide deformylase: 0.0025 mM, designed based on the best substrate identified
-
Thiophenol
-
IC50: 0.5 mM
thiram
-
-
thyropropic acid derivatives
-
IC50 against Escherichia coli peptide deformylase: 0.001 mM
-
urea analogs(P2'/P3')of N-formyl hydroxylamine
-
-
Vancomycin
VIC-104959